ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / CBLL / earnings
CNMD (65) INMD (58) TMDX (62) AXGN (54) ⌘ Pro Terminal →

CeriBell Inc. (CBLL) Next Earnings Date & Expected ±11.5% Move

$26.58 -4.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $26.32

CeriBell Inc. (CBLL) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $1.07B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CBLL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CBLL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, CeriBell Inc. (NASDAQ: CBLL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $26.58 (-4.46% 1D, market cap $1.07B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CBLL ranks #403 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CBLL compare to CNMD and INMD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), CBLL carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 87.9%, and ROIC of -35.0%. By comparison, CNMD (CONMED Corporation) holds a C grade (65/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.36B) and INMD (InMode Ltd.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC 17.7%, cap $776.6M). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CBLL?
▼

Per CBLL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001861107), CeriBell Inc. generated $89.1M in revenue (+36.1% YoY), -$53.4M in net income, and -$41.6M in free cash flow against $195.8M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $26.32 (-0.99%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D
Cash (8)Whales (16)SEC (11)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-5.8% Base Target
$30 Bull$25 Base$20 Bear
📬 FREE CBLL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CBLL)Realized 20D OHLCV Swing Band: ±11.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY CBLL SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (36% of score)

20D Institutional Volume Accumulation (±11.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (24% of score)

Altman Z-Score 14.75 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$25.26+2.9% Next Q
Q2 (-2Q)
40
Grade D$26.00+4% Next Q
Q3 (-1Q)
42
Grade D$27.03-1.7% Next Q
Current
45
Grade D$26.58-6.3% Hist 90D α
Trajectory: E (37) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CBLL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CBLL currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($25.00) and Max Pain ($27.91) forces dealer call-delta covering toward $29.60.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CBLL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CBLL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±11.5% Swing Band

±$3.06 Expected Swing
$23.52 (-11.5%)Spot $26.58$29.64 (+11.5%)
MODEL EARNINGS SETUP GAUGE

CBLL Quantitative Pre-Earnings Setup: 45/100

Trailing EPS: $4.25 • YoY Revenue Growth: 36.1%

Model Bullish Setup (45/100)Model Risk Weight (55/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$89.1M-$53.4M-$41.6M87.9%
FY 20242024-12-31$65.4M-$40.5M-$36.4M86.7%
FY 20232023-12-31$45.2M-$29.5M-$29.2M87.9%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CBLL)

  • ✓Walkthrough of CBLL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CBLL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +31.13%📐 HORIZONTAL RANGE
2026-11-02O $27.22H $27.82L $26.58C $26.58VOL 405.3K
RES: $28.62SUP: $22.42SMA50: $25.00SMA200: $20.80
$29.05$25.47$21.89$18.31$14.73RES $28.62SUP $22.42$26.582026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CBLL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CBLL Butterfly Map → + Track CBLL →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +36.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CBLL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CBLL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CBLL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CBLL)

Health Care Rank #403 of 1016 ⚔️ CNMD vs CBLL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CBLL vs. CNMD, INMD, TMDX, AXGN)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CeriBell Inc. (CBLL) ranks #403 by composite RQD confidence (45/100, grade D) and #357 by equity capitalization ($1.07B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. CNMD currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with CBLL at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CBLL ACTIVE
CeriBell Inc.
D 45/100 — 87.9% -35.0% -4.46% $1.07B Benchmark Subject
CNMD
CONMED Corporation
C 65/100 28.9x 54.6% 7.8% -3.13% $1.36B /cnmd-vs-cbll →
INMD
InMode Ltd.
D+ 58/100 — 78.5% 17.7% -2.15% $776.6M /inmd-vs-cbll →
TMDX
TransMedics Group Inc.
C 62/100 12.2x 59.9% 18.1% -1.68% $2.33B /tmdx-vs-cbll →
AXGN
Axogen Inc.
D+ 54/100 — 74.3% -2.6% -0.52% $2.96B /axgn-vs-cbll →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001861107

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CeriBell Inc. (CBLL) reported GAAP revenue of $89.1M (+36.1% vs. FY2024 revenue of $65.4M , and +96.9% cumulative change since FY2023) , GAAP net income of -$53.4M, operating cash flow of -$40.8M, and free cash flow of -$41.6M (-14.3% YoY). On the balance sheet, CBLL closed FY2025 with $195.8M in total assets against $0 in total debt (Altman Z-Score: 14.75, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $89.1M -$53.4M -$40.8M -$41.6M $195.8M —
FY2024 (FY) 2024-12-31 $65.4M -$40.5M -$35.0M -$36.4M $225.4M —
FY2023 (FY) 2023-12-31 $45.2M -$29.5M -$29.2M -$29.2M — —

3. CBLL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CBLL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, CeriBell Inc. (NASDAQ: CBLL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $26.58 (-4.46% 1D, market cap $1.07B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CBLL ranks #403 in composite RQD confidence.

How does CBLL compare to CNMD and INMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), CBLL carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 87.9%, and ROIC of -35.0%. By comparison, CNMD (CONMED Corporation) holds a C grade (65/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.36B) and INMD (InMode Ltd.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC 17.7%, cap $776.6M). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CBLL?

Per CBLL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001861107), CeriBell Inc. generated $89.1M in revenue (+36.1% YoY), -$53.4M in net income, and -$41.6M in free cash flow against $195.8M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CBLL trading relative to its 50-day, 200-day, and 52-week technical levels?

CBLL last traded at $26.58 (-4.46% on volume of 582,672 shares), positioning the stock +6.32% above its 50-day simple moving average ($25.00) and +27.79% above its 200-day simple moving average ($20.80). Across its 52-week range of $10.85 to $28.19, CBLL sits at the 90.7% percentile with a 14-day RSI of 59.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.5% ($23.52 to $29.64).

CBLL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is CBLL's next earnings date?

Based on SEC filing cadence, CeriBell Inc. (CBLL)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is CBLL stock expected to move on earnings?

Volatility modeling currently projects a ±11.5% event move for CBLL, spanning a range between $23.52 and $29.64.

Direct Sub-Reports: CBLL RQD Cockpit CBLL 12M Forecast CBLL Earnings & Move CBLL Dividends & DRIP CBLL Insiders & 13F CBLL Whale Options CBLL Profit Sankey CBLL News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CBLL — CeriBell Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:30:58Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CBLL scores 45 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

  • Fundamental Cash Engine: 8 / 20. Per the RQD rating, this pillar reflects ROIC of -35% and an FCF yield of -3.89%. For a prospective investor, the cash engine is the weakest link: the company is not currently generating returns on invested capital or free cash flow to support the valuation.
  • Whale 13F Flow: 16 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. This is the strongest pillar and suggests some institutional interest, though the source data does not itemize 13F holders (see Analyst View section).
  • Insider Conviction: 3 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider conviction signals in the data.
  • Macro Regime Fit: 7 / 20. Per the RQD rating, this pillar reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broader market; the low score reflects limited regime-based support.
  • Forensic Balance Sheet: 11 / 20. Per the RQD rating, this pillar reflects an Altman Z-Score of 14.75, a Piotroski F-Score of 4/9, and a Debt/Equity ratio of 0.5. The balance sheet is a relative bright spot, though the Piotroski score is mid-range.

Taken together, the investor implication is that the stock's recent price strength (52-week range of $10.85 to $28.19, with the current price of $27.82 near the top of that range) is not supported by the operating cash-flow fundamentals as measured in the RQD framework. Valuation tradeoffs are significant: with no reported P/E or EPS in the source data, the investor cannot benchmark the price against earnings. Upside drivers in the data are limited to institutional positioning and the balance-sheet strength; downside risks center on sustained cash burn and the distribution warning verdict.

Business

Per the company profile, CeriBell Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Per the market data, the company reports a gross margin of 87.9%. Not available in source data for specific products, customers, or revenue-generation detail beyond the reported financial lines.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$89.1M$-58.4M$-53.4MN/A$-41.6M$40.5MN/A
FY 2024$65.4M$-39.7M$-40.5MN/A$-36.4M$194.4MN/A
FY 2023$45.2M$-30.0M$-29.5MN/A$-29.2MN/AN/A

Per the SEC financials, revenue grew from $45.2M (FY 2023) to $65.4M (FY 2024) to $89.1M (FY 2025), while operating losses widened from $-30.0M to $-39.7M to $-58.4M. Per the market data, the operating margin and net margin are both -60%, and ROIC is -35%. Per the RQD rating, the Altman Z-Score is 14.75 and the Piotroski F-Score is 4/9, with a Debt/Equity ratio of 0.5. Reported cash declined from $194.4M (FY 2024) to $40.5M (FY 2025).

Recent Catalysts & News Wire Analysis

Per the news wire, recent headlines reference an FDA clearance for CeriBell and a one-year share price run of 133%, with multiple outlets questioning whether the stock is fully priced. All six items are tagged YELLOW with a "MARKET WIRE" impact label. Key catalysts: FDA clearance (per headline references). Risk watch items: valuation concerns raised across multiple headlines. Per the Butterfly Supply-Chain Graph, there are no proprietary signals in the source data.

Open Questions

  • What drives the FY 2025 cash decline from $194.4M to $40.5M, and what is the company's runway at the reported FY 2025 FCF of $-41.6M?
  • What are the reported EPS, P/E, and EV/EBITDA figures, which are absent from the source data?
  • Which institutional holders and insiders account for the Whale 13F and Insider Conviction pillar scores?
  • What is the debt balance behind the reported Debt/Equity ratio of 0.5, since debt is listed as N/A for all periods?
  • What is the commercial significance of the FDA clearance referenced in the news wire, and how does it translate into revenue?

CBLL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for CeriBell Inc. (CBLL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CBLL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CBLL Bull vs. Bear Conversation Board — What's Your Call at $26.58?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CBLL 🐻 67% BEARISH CONVICTION
1. Pick Your Side on CBLL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $24.48 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CBLL (D • RQD 45/100) a Buy at $27.82?

Welcome to the CBLL (CeriBell Inc.) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Electromedical & Electrotherapeutic Apparatus. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $21.42 (-23.0%)
Spot @ $27.82

Pump the brakes on CBLL — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CBLL, but look at what you are paying: current EV/EBITDA multiples with 87.9% gross margins. Unless CeriBell Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $35.05 (+26.0%)
Spot @ $27.82

CBLL cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CBLL, the market is fixating on short-term headline noise in Biotechnology: Electromedical & Electrotherapeutic Apparatus and ignoring the balance sheet and cash flow trajectory. At $27.82 (52-wk range $10.85 - $28.19), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%